#Italianpharma group #Chiesi has named #DavidKhougazian as its new permanent #chiefexecutive, following the departure of Giuseppe Accogli earlier this year to join private equity firm Archimed.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#Italianpharma group #Chiesi has named #DavidKhougazian as its new permanent #chiefexecutive, following the departure of Giuseppe Accogli earlier this year to join private equity firm Archimed.
@pharmaphorum.bsky.socialThe offer on the table for #Italianpharma group #Recordati by #privateequity firms #CVC and #GBL undervalues the company and is unfair to minority #shareholders, according to #hedgefund #Palliser, which is leading a pushback against the deal.